Abstract
Many biologic agents that were first approved for the treatment of malignancies are now being actively investigated and used in a variety of autoimmune diseases such as rheumatoid arthritis (RA), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, systemic lupus erythematosus (SLE), and Sjogren's syndrome. The relatively recent advance of selective immune targeting has significantly changed the management of autoimmune disorders and in part can be attributed to the progress made in understanding effector cell function and their signaling pathways. In this review, we will discuss the recent FDA-approved biologic therapies that directly target immune cells as well as the most promising investigational drugs affecting immune cell function and signaling for the treatment of autoimmune disease.
MeSH terms
-
Animals
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Arthritis, Rheumatoid / drug therapy
-
Arthritis, Rheumatoid / immunology
-
Autoimmune Diseases / drug therapy*
-
Autoimmune Diseases / immunology*
-
Autoimmunity / drug effects*
-
Autoimmunity / immunology
-
B-Lymphocytes / drug effects
-
B-Lymphocytes / immunology
-
Biological Therapy
-
Humans
-
Immunity, Cellular / drug effects*
-
Immunosuppressive Agents / therapeutic use
-
Lupus Erythematosus, Systemic / drug therapy
-
Lupus Erythematosus, Systemic / immunology
-
Protein-Tyrosine Kinases / drug effects
-
Protein-Tyrosine Kinases / immunology
-
Rituximab
-
Sjogren's Syndrome / drug therapy
-
Sjogren's Syndrome / immunology
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Immunosuppressive Agents
-
Rituximab
-
Protein-Tyrosine Kinases